TABLE 1.
characteristics of included studies.
| Source | Study period | Total (experimental/control) no. of patients | Experimental/control age, mean (SD), y | Intervention/daily dosage | Treatment period, day | Outcomes a |
|---|---|---|---|---|---|---|
| Qian et al. (2010) | 2007.1–2009.6 | 59 (29/30) | 78.5(5.8)/77.9(6.9) | Reduning/20 ml | 7 | ①② |
| Chen and Li (2011) | 2006.1–2009.12 | 60 (30/30) | 64 (35) | Xuebijing/100 ml | 7 | ① |
| Liang and Peng (2011) | 2008.5–2010.5 | 56 (28/28) | 57.2(10.8)/58.3(10) | Xuebijing/200 ml | 7 | ①③ |
| Cao (2012) | 2010.9–2011.12 | 80 (40/40) | 65.7/66.3 | Shenmai/50 ml | 10 | ②④⑥ |
| Jiang et al. (2012) | 2008.8–2010.8 | 59 (29/30) | 42(13)/43(11) | Xuebijing/150 ml | 7 | ②⑤ |
| Liang (2012) | 2010.11–2011.4 | 70 (35/35) | 39.6 (8.3) | Xuebijing/200 ml | 7 | ② |
| Liu et al. (2012) | 2008.1–2010.7 | 172 (91/81) | 55/53 | Xuebijing/200 ml | 7 | ①②③④⑤⑥ |
| Ma (2012) | 2009.1–2012.1 | 60 (30/30) | 57.5(8.3)/57.2(8.7) | Xuebijing/100 ml | 7 | ②③④⑤ |
| Tian and Sun (2012) | 2010.1–2011.1 | 100 (50/50) | 39.5 (3.7) | Xuebijing/100 ml | 7 | ①③④ |
| Zhang et al. (2012) | 2009.11–2011.9 | 60 (30/30) | 66.9 (17.3) | Danshen/30 ml | 5 | ①②③⑤ |
| Chen et al. (2013) | — | 100 (50/50) | 50(15.1)/52.4(15.9) | Danshen/30 ml | 7 | ② |
| Li et al. (2013) | 2011.6–2013.1 | 60 (30)/(30) | 46.2(17.9)/40.3(15.3) | Huangqi/20 ml | 7 | ①④⑤⑥ |
| Li (2013) | 2012.5–2013.4 | 40 (20/20) | 65.2(12.6)/66.6(10.1) | Tanreqing/20 ml | 7 | ⑤⑥ |
| Yang (2013) | 2010.3–2012.4 | 124 (62/62) | 44.1(7.5)/43.5(6.7) | Tanreqing/20 ml | 7 | ①②⑤ |
| Zhang (2014) | 2009.1–2014.2 | 47 (23/24) | 44(7.5)/43.6(6.7) | Tanreqing/20 ml | 7 | ② |
| Wang et al. (2015) | 2014.1–2014.10 | 100 (50/50) | 42.2(4.1)/43.4(4.6) | Huangqi/20 ml | 5 | ③④ |
| He (2016) | 2015.1–2016.4 | 84 (42/42) | 58(9)/59(10) | Xuebijing/100 ml | 7 | ②⑤ |
| Lin et al. (2016) | 2013.6–2015.7 | 80 (40/40) | 48.7 (8.8) | Fufangkushen/30 ml | - | ①②④ |
| Liu et al. (2016) | 2013.1–2016.4 | 60 (30/30) | 54.3(5.9)/53.8(6.2) | Xuebijing/100 ml/150 ml | 14 | ②③④ |
| Deng (2017) | 2015.5–2016.5 | 70 (35/35) | 42(6)/42(7) | Xuebijing/150 ml | 7 | ②⑤ |
| Gou et al. (2017) | 2012.8–2014.10 | 40 (20/20) | 40.6/45.2 | Xuebijing/200 ml | 7 | ② |
| Guo et al. (2018) | 2013.12–2017.12 | 136 (68/68) | 51.1(11.1)/49(9.2) | Tanreqing/20 ml | 7 | ② |
| Wang (2018) | — | 132 (66/66) | 62.6(3.2)/62.5(2.4) | Xuebijing/100 ml | 7 | ⑤⑥ |
| Zhen et al. (2019) | 2016.6–2018.6 | 64 (32/32) | 53.4(6.2)/52.3(7.7) | Xuebijing/100 ml | 7 | ②③④⑤ |
| Chang et al. (2019) | 2016.1–2019.1 | 60 (30/30) | 51.3(7.2)/53.6(7.9) | Xuebijing/100 ml | 7 | ①② |
| Lang and Lei, (2019) | 2017.7–2018.8 | 100 (50/50) | 47.3(3.4)/46.4(3.5) | Xuebijing/150 ml | 7 | ② |
aOutcome ① mortality; ② PaO2/FiO2 in 7 days after treatment; ③ length of ICU stay; ④ duration of mechanical ventilation; ⑤ APACHEII score; ⑥ Murray score.